Medicare should prioritize access to Alzheimer’s drugs because these medications can significantly improve the quality of life for patients in the early stages of the disease. Investing in these treatments can lead to better outcomes and potentially reduce overall healthcare costs in the long run by delaying the need for more intensive care.